131 related articles for article (PubMed ID: 24593893)
1. Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499.
Ando H; Asai T; Koide H; Okamoto A; Maeda N; Tomita K; Dewa T; Minamino T; Oku N
J Control Release; 2014 May; 181():32-9. PubMed ID: 24593893
[TBL] [Abstract][Full Text] [Related]
2. Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy.
Ando H; Okamoto A; Yokota M; Shimizu K; Asai T; Dewa T; Oku N
J Gene Med; 2013 Jan; 15(1):20-7. PubMed ID: 23239404
[TBL] [Abstract][Full Text] [Related]
3. Polycation liposomes as a vector for potential intracellular delivery of microRNA.
Ando H; Okamoto A; Yokota M; Asai T; Dewa T; Oku N
J Gene Med; 2013 Oct; 15(10):375-83. PubMed ID: 24105805
[TBL] [Abstract][Full Text] [Related]
4. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Lu ZX; Liu LT; Qi XR
Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Efficacy of Doxorubicin by microRNA-499-Mediated Improvement of Tumor Blood Flow.
Okamoto A; Asai T; Ryu S; Ando H; Maeda N; Dewa T; Oku N
J Clin Med; 2016 Jan; 5(1):. PubMed ID: 26797645
[TBL] [Abstract][Full Text] [Related]
6. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
Maeda N; Takeuchi Y; Takada M; Sadzuka Y; Namba Y; Oku N
J Control Release; 2004 Nov; 100(1):41-52. PubMed ID: 15491809
[TBL] [Abstract][Full Text] [Related]
7. Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA delivery.
Asai T; Matsushita S; Kenjo E; Tsuzuku T; Yonenaga N; Koide H; Hatanaka K; Dewa T; Nango M; Maeda N; Kikuchi H; Oku N
Bioconjug Chem; 2011 Mar; 22(3):429-35. PubMed ID: 21361311
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of PTEN-positive metastatic tumors to small interfering RNA targeting the mammalian target of rapamycin.
Koide H; Asai T; Kato H; Yonenaga N; Yokota M; Ando H; Dewa T; Nango M; Maeda N; Oku N
Nanomedicine; 2015 Jan; 11(1):185-94. PubMed ID: 25240598
[TBL] [Abstract][Full Text] [Related]
9. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment.
Yonenaga N; Kenjo E; Asai T; Tsuruta A; Shimizu K; Dewa T; Nango M; Oku N
J Control Release; 2012 Jun; 160(2):177-81. PubMed ID: 22019557
[TBL] [Abstract][Full Text] [Related]
10. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer.
Wang Y; Liu P; Duan Y; Yin X; Wang Q; Liu X; Wang X; Zhou J; Wang W; Qiu L; Di W
Biomaterials; 2014 Jan; 35(3):983-92. PubMed ID: 24176193
[TBL] [Abstract][Full Text] [Related]
11. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
[TBL] [Abstract][Full Text] [Related]
12. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin.
Shimizu K; Asai T; Fuse C; Sadzuka Y; Sonobe T; Ogino K; Taki T; Tanaka T; Oku N
Int J Pharm; 2005 May; 296(1-2):133-41. PubMed ID: 15885465
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels.
Ichikawa K; Hikita T; Maeda N; Yonezawa S; Takeuchi Y; Asai T; Namba Y; Oku N
Biochim Biophys Acta; 2005 May; 1669(1):69-74. PubMed ID: 15843001
[TBL] [Abstract][Full Text] [Related]
14. A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy.
Murase Y; Asai T; Katanasaka Y; Sugiyama T; Shimizu K; Maeda N; Oku N
Cancer Lett; 2010 Jan; 287(2):165-71. PubMed ID: 19616372
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy.
Guo P; Song S; Li Z; Tian Y; Zheng J; Yang X; Pan W
Int J Pharm; 2015; 486(1-2):356-66. PubMed ID: 25840274
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic photodynamic therapy with targeted liposomes.
Oku N; Ishii T
Methods Enzymol; 2009; 465():313-30. PubMed ID: 19913174
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Katanasaka Y; Ida T; Asai T; Shimizu K; Koizumi F; Maeda N; Baba K; Oku N
Cancer Lett; 2008 Nov; 270(2):260-8. PubMed ID: 18555591
[TBL] [Abstract][Full Text] [Related]
18. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78.
Katanasaka Y; Ishii T; Asai T; Naitou H; Maeda N; Koizumi F; Miyagawa S; Ohashi N; Oku N
Int J Cancer; 2010 Dec; 127(11):2685-98. PubMed ID: 20178102
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice.
Kim WJ; Yockman JW; Jeong JH; Christensen LV; Lee M; Kim YH; Kim SW
J Control Release; 2006 Sep; 114(3):381-8. PubMed ID: 16884805
[TBL] [Abstract][Full Text] [Related]
20. Chronopharmacologic cancer treatment with an angiogenic vessel-targeted liposomal drug.
Shimizu K; Sawazaki Y; Tanaka T; Asai T; Oku N
Biol Pharm Bull; 2008 Jan; 31(1):95-8. PubMed ID: 18175949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
